ARS Pharmaceuticals opened lower at $3.90, compared with its previous close of $3.95. In the last trading session, the stock traded between $3.80 and $4.11. It showed a downward intraday trend.
An investment of $100 made 5 years ago in ARS Pharmaceuticals is now worth
$ 62.92
Resulting in a loss of
$ 37.08 (37.08%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.14 (-3.47%)
Day High
$4.11
Day Low
$3.80
Day Open
$3.90
Prev Close
$3.95
Volume
19,71,685
1W Return
25.39%
1M Return
-8.69%
3M Return
-36.08%
6M Return
-55.66%
1Y Return
-56.52%
Market Cap ($ Mn)
383
PE Ratio
-
PB Ratio
46.73
PEG Ratio
-
ROE
-91.12%
ROCE
-59.59%
EPS (TTM)
$-0.35
1 Week
25.39%
1 Month
-8.69%
3 Months
-36.08%
6 Months
-55.66%
9 Months
-59.86%
Cantor Fitzgerald maintains Overweight on ARS Pharma, cuts PT to $20
Cantor Fitzgerald maintains Overweight rating on ARS Pharmaceuticals. Price target lowered from $30 to $20 following Q3 FY26 results. Raymond James downgraded stock to Outperform with $17 price target. Total revenue rose 16% YoY to $37.7 million in Q3 FY26.
6 days agoARS Pharmaceuticals investor deadline Monday as class action widens
Investors have until October 5, 2026, to file for lead plaintiff status in the ARS Pharmaceuticals securities class action. The lawsuit covers share purchases between March 9, 2026, and June 24, 2026, following a 23.9% stock drop. Faruqi & Faruqi, LLP partner Josh Wilson encourages affected investors to contact him directly to discuss legal options. The complaint alleges false statements regarding CVS Caremark insurance coverage timelines for the drug neffy.
1mo agoGrabar Law probes ARS Pharma, Bloom Energy, GPGI, Insulet claims
Grabar Law Office has expanded its shareholder investigations to include GPGI, Inc., alongside existing probes into ARS Pharmaceuticals, Bloom Energy, and Insulet Corporation. The firm alleges fiduciary breaches involving misleading disclosures on coverage timelines, supply chain origins, acquisition valuations, and manufacturing defects.
2mo agoARS Pharma Q2 revenue up 114% to $33.7m; net loss widens to $62.3m
Ars Pharmaceuticals posted Q2 2026 revenue of $33.7 million, up 114% YoY, but net loss widened to $62.3 million. The firm pivots to targeted provider sales, aiming for cash flow breakeven by late 2027 through >40% SG&A cuts in H2.
3mo agoARS Pharma to Report Q2 2026 Results on Aug 13 Call
ARS Pharmaceuticals announced a conference call on August 13, 2026, for Q2 2026 results. CEO Donn Casale will discuss financial outcomes and updated strategic priorities. The event includes a webcast with a 30-day replay.
3mo agoPomerantz investigates ARS Pharmaceuticals over Neffy coverage
Pomerantz LLP is investigating ARS Pharmaceuticals Inc. over potential securities fraud related to misleading statements about the commercial coverage of Neffy. The investigation follows a 23.91% stock drop after the company failed to secure new formulary additions on July 1, 2026, contradicting earlier executive guidance. Despite the setback, analysts maintain an Outperform rating, citing solid commercial execution and potential growth in chronic spontaneous urticaria.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in ARS Pharmaceuticals is now worth
$ 62.92
Resulting in a loss of
$ 37.08 (37.08%)
Note: Past profits do not guarantee future returns.
